PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.36 +0.76%

+$0.60 today

Market cap
$5.04B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 1.08M

Average 1.27M

PTCT EBITDA Margin

EBITDA as a percentage of revenue.

PTC Therapeutics, Inc.NASDAQ: PTCT

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 44.9%

EBITDA Margin was 44.9% in Q2 FY2026, up 63.4 pp from a year earlier. On a trailing-twelve-month basis it was 17.2%, down 30.5 pp year over year. Over 3 fiscal years it widened by 103.9 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 23.5% for the fiscal year ending Dec 2026, down from 51.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
44.9%+22.2 pp QoQ
Last fiscal yearDec 2025
51.3%+66.2 pp YoY
LTMJun 2026
17.2%-30.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+63.4 pp+15.6 pp-47.8 pp
1 year+66.2 pp-27.8 pp-94.1 pp
3 years+103.9 pp-6.9 pp-110.9 pp
5 years-1.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
51.3%
Year-over-year change
+66.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's LTM Jun 2026 EBITDA Margin of 17.2% is the 2nd highest of the 8 companies compared; the peer median is -49.3%.
  • Its year-over-year change of -30.5 pp is the 5th highest of 8, against a peer median of -0.2 pp.
  • Over three fiscal years its change of +103.9 pp compares with a peer median of +70.1 pp.
PTCT Competitors Peer median
EBITDA Margin for PTCT and competitors
Company Period LTM level YoY 3-year change
KRYSKrystal Biotech, Inc.LTM Jun 202649.9% -0.2 pp—
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-8.0% -32.9 pp+5.1 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-75.2% +1.0 pp+105.9 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-85.7% +187.2 pp+377.1 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-243.2% -144.4 pp+3681.3 pp
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
Peer median (excluding PTCT) -49.3%-0.2 pp+70.1 pp

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue538.59M698.8M937.82M806.78M1.73B
Cost of Revenue32.33M44.68M65.49M57.4M71.76M
Gross Profit506.27M654.12M872.34M749.38M1.66B
Gross Margin94.0%93.6%93.0%92.9%95.9%
Research & Development540.68M651.5M666.56M534.48M455.25M
Selling, General & Admin285.77M326M332.54M300.91M347.14M
Operating Expenses880.71M1.1B1.31B1.05B802.39M
Depreciation & Amortization64.13M128.84M236.59M75.66M38.82M
EBITDA(368.18M)(367.78M)(330.34M)(120.46M)887.66M
EBITDA Margin-68.4%-52.6%-35.2%-14.9%51.3%
Operating Income(374.44M)(447.41M)(439.5M)(302.57M)856.51M
Operating Margin-69.5%-64.0%-46.9%-37.5%49.5%
Interest Income00000
Interest Expense86.02M90.87M129.18M166.99M152.23M
Other Income / Expenses(143.9M)(140.08M)(256.61M)(60.55M)(159.89M)
Income Before Tax(518.34M)(587.49M)(696.11M)(363.12M)696.62M
Pre-Tax Margin-96.2%-84.1%-74.2%-45.0%40.3%
Income Tax Expense5.56M(28.47M)(69.51M)176K13.98M
Net Income(523.9M)(559.02M)(626.6M)(363.3M)682.64M
Net Margin-97.3%-80.0%-66.8%-45.0%39.4%
EPS (Basic)(7.43)(7.79)(8.37)(4.73)8.58
EPS (Diluted)(7.43)(7.79)(8.37)(4.73)7.78
Weighted Avg Shares70.47M71.73M74.84M76.85M79.53M
Weighted Avg Shares (Diluted)70.47M71.73M74.84M76.85M88.31M

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.